Adjuvant Nivolumab Versus Ipilimumab in Resected Stage III/IV Melanoma: 5-Year Efficacy and Biomarker Results From CheckMate 238.
James M G LarkinMichele Del VecchioMario MandalaHelen J GogasAna M AranceStéphane DalleCharles Lance CoweyMichael SchenkerJean-Jacques GrobVanna Chiarion SileniIvan Marquez-RodasMarcus O ButlerAnna Maria Di GiacomoMark Ross MiddletonJose LutzkyLuis de la Cruz MerinoPetr ArenbergerVictoria AtkinsonAndrew G HillLeslie A FecherMichael MillwardPaul D NathanNikhil I KhushalaniPaola QueiroloCorey RitchingsMaurice LoboMargarita AskelsonHao TangSonia DolfiPaolo Antonio AsciertoJeffrey S WeberPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2023)
NIVO is a proven adjuvant treatment for resected melanoma at high-risk of recurrence, with sustained, long-term improvement in RFS and DMFS compared with IPI and high OS rates. Identification of additional biomarkers are needed to better predict treatment outcome.